Acute treatment of atrial fibrillation

American Journal of Cardiology

Volumn 81, Issue 5 A, 1998, Pages 16C-22C

  Kowey, Peter R ^a   Marinchak, Roger A ^b   Rials, Seth J ^b   Filart, Roland A ^b  

^a Lankenau Medical Office Building East   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

CARDIOVERSION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0032510306     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00182-9     Document Type: Conference Paper

References (65)

1. Bialy D, Lehmann MH, Schumacker DN, Steinman RT, Meissner MD. Hospitalizations for arrhythmias in the United States: importance of atrial fibrillation. (Abstr.) J Am Coll Cardiol 1992;19:41A.
2. Nattel S. Newer developments in the management of atrial fibrillation. Am Heart J 1995;130:1094-1106.
3. Allesie MA. Electrophysiological sequelae of atrial fibrillation. In: Kulbertus HE, Wellens HJJ, Bourgeois IMGP, Sutten R, eds. Atrial Fibrillation - Facts From Yesterday - Ideas for Tomorrow. New York: Futura Publishing, 1994:74.
4. Geraets DR, Kienzle MG. Atrial fibrillation and atrial flutter. Clin Pharmacol 1993;12:721-735.
5. Falk RH. Atrial fibrillation. In: Podrid PJ, Kowey PR, eds. Cardiac Arrhythmia: Mechanisms Diagnosis and Management Maryland: Williams and Wilkins, 1995:803-827.
6. Lavy S, Stern S, Melamed E, Cooper G, Keren A, Levy P. Effect of chronic AF on regional cerebral blood flow. Stroke 1980;11:35-38.
7. Peterson P, Kastrup J, Videlback R, Boyser G. Cerebral blood flow before and after CV of atrial fibrillation. J Cereb Blood Flow Metab 1989;9:422-425.
8. Falk RH, Lesvitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med 1991;114:573-575.
9. Smith TW. Digital glycoside. N Engl J Med 1973;288:719-722.
10. Falk RH, Knowlton AA, Bernard S, Gotiel NE, Battinelli NJ. Digoxin for converting recent onset atrial fibrillation to sinus rhythm - a randomized double blinded trial. Ann Intern Med 1987;106:503-506.
11. Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of "therapeutic" serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 1975;35:651-655.
12. Modell W, Gold H, Rothendler HH. Use of digitals to prevent exaggerated acceleration of the heart. JAMA 1941;116:2241-2244.
13. Rawels JM, Metcalfe MJ, Jennings K. Time of occurrence, duration and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990;63:225-227.
14. Lundström T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86-90.
15. Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise induced tachycardia in patients with atrial fibrillation receiving digitals. Am J Cardiol 1983;52:1197-1201.
16. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986;73:316-324.
17. Falk RH. Control of the ventricular rate in atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press, 1992:255-282.
18. Sum CY, Yacobi A, Kartzinel R, Stampfi H, Davis CS, Lai C-M. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 1983;34:427-433.
19. Anderson S, Blanski L, Byrd RC, Das G, Engler R, Laddu A, Lee R, Rajfer S, Schroeder J, Stech J, Sung R, Turlapary P, Williams D, Wilner G, Zoble R. Comparison of the efficacy and safety of esmolol, a short acting beta-blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986;111:42-48.
20. Salerno DM, Dias VC, Kleiger RE, Tschida V, Sung R, Sami M, Giorgi L. The diltiazem - atrial fibrillation/flutter study group. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. Am J Cardiol 1989;63:1046-1051.
21. Waxman HC, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double blind randomized cross-over study. Ann Intern Med 1981;94: 1-6.
22. Coumel P. Neural aspect of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press, 1992:111-112.
23. Mandel WJ, Laks MM, Obayashi K, Hayakawa H, Daley W. The Wolff-Parkinson-White Syndrome: pharmacologic effects of procaine amide. Am Heart J 1975;90:744-754.
24. Wellens HJJ. The wide QRS tachycardia. Ann Intern Med 1986;104:879.
25. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-338.
26. Suttorp MJ, Kingma JH, Jealous ER, Lei-A-Huen L, van Hemel N, Lie K. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-1727.
27. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989;63:693-696.
28. Wellens HJJ, Brugada P, Abdollah H, Dassen WR. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 1984;69:120-124.
29. Installe E, Schoevaerdts JC, Gadisseux PH, Charles S, Tremouroux J. Intravenous amiodarone in treatment of various arrhythmias following cardiac operations. J Thorac Cardiovasc Surg 1981;81:302-308.
30. Blandford RL, Crampton J, Kudlac C. Intravenous amiodarone in atrial fibrillation complicating myocardial infarction. Br Med J 1982;284:16-17.
31. Cochrane AD, Siddins M, Rosenfedt FL, Salamonsen R, McConaghy L, Marasco S, Davis BB. A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery. Eur J Cardiothorac Surg 1994;8:194-198.
32. Galve E, Rius T, Ballester R, Arau JM, Artaza MA, Soler-Soler J, Intravenous amiodarone for acute conversion of digoxin treated paroxysmal atrial fibrillation to sinus rhythm. A randomized controlled study. (Abstr.) Circulation 1992;86:I-665.
33. Donovan KD, Power BM, Hockings BEF, Dobbs G, Lee K-Y. Intravenous flecainide versus amiodarone for recent onset atrial fibrillation. Am J Cardiol 1995;75:693-697.
34. Bjerkeland CJ, Orning OM. The efficacy of anticoagulation therapy in preventing embolism related to direct current electrical cardioversion of atrial fibrillation. Am J Cardiol 1969;23:208-216.
35. Arnold AZ, Mick MJ, Mazurek RP. Role of prophylactic anti coagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992;19:851-855.
36. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992;102(suppl):426S-433S.
37. Black IW, Hopkins AD, Lee LCL, Walsh WF. Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in non-anticoagulated patients. Am Heart J 1993;126:375-381.
38. Fatkin D, Kuchar D, Thorburn C, Feneley M. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994;23:307-316.
39. Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol 1996;78:435-439.
40. Hata JS, Aryres RW, Biller J, Adams HP, Stuhlmuller J, Burns T, Kerber R, Vanderberg B. Impact of transesophageal echocardiographic on the anticoagulation management of patients admitted with focal cerebral ischemia. Am J Cardiol 1993;72:707-710.
41. Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993;328:750-755.
42. Black IW, Hopkins AD, Lee LCU, Walsh WF. Thromboembolic risk of atrial flutter. (Abstr.) J Am Coll Cardiol 1992;19:314A.
43. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994;48:345-371.
44. Hillestad L, Bjerkelurd C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electrocardioversion of chronic atrial fibrillation. A control clinical study. Br Heart J 1971;33:518-521.
45. Halpern SW, Ellrodt G, Singh BN, Mandel W. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. Br Heart J 1980;44:589-595.
46. Fenster PE, Comess KA, Marsh R, Katzenberg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983;106:501-504.
47. Fuchs T, Podrid PJ. Pharmacologic therapy for reversion of atrial fibrillation and maintenance of sinus rhythm. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press, 1992:235-254.
48. Volgman AS, Stambler BS, Kappagoda C, Carberry PA, Dunn GH, Perry KT, Vanderlugt JT, Kowey PR. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter. (Abstr.) PACE 1996;19:608.
49. Goy JJ, Kaufman U, Kappenberger L, Sigwart U. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988;62:38D-40D.
50. Capucci A, Lenzi T, Boriani G, Trisolino G, Binett N, Cavazza M, Fontana G, Magnani B. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
51. Marcus FI. The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 1990;66:366-367.
52. Murdock CJ, Kyles AE, Yeung-dai-uah JA, Qi A, Varderbrugger S, Kerr CR. Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990;66:755-757.
53. Cochrane AD, Siddins M, Rosenfieldt FL, McConaghy L, Marasco S, Davis B. A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery. Eur J Cardiothoracic Surg 1994;8:194-198.
54. Horner SM. A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion. Acta Cardiologica 1992;5:473-480.
55. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute cardioversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990;65:679-680.
56. Podrid PJ. Oral antiarrhythmic drugs used for atrial fibrillation, clinical pharmacology. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press, 1992:197-231.
57. Juul-Moller S, Edvardsson N, Rehngvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation. Circulation 1990;82:1932-1939.
58. Kowey PR, Vanderlugt JT, Luderer JR. Ibutilide for acute conversion of atrial fibrillation/flutter safety and risk benefit analysis. Am J Cardiol 1996;78(suppl 8A):46-52.
59. Falk RH, Podrid PJ. Electrical cardioversion of atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press, 1992:184-195.
60. Levy S, Lacombe P, Cointe R, Bru P. High energy transcatheter cardioversion of chronic atrial fibrillation. J Am Coll Cardiol 1988;12;514-518.
61. Kowey PR. The calamity of cardioversion of conscious patients. Am J Cardiol 1988;61:1106-1107.
62. Waldo AL. Atrial flutter. In: Podrid PJ, Kowey PK, eds. Cardiac Arrhythmia: Mechanisms, Diagnosis and Management. Maryland: Williams and Wilkins, 1995:790-802.
63. Hung-Fat T, Chu-Pak L, Adler S, Kim J. The efficacy for atrial fibrillation detection and R wave synchronization for shock delivery in patients with implantable human atrial defibrillation. (Abstr.) Circulation 1996;94:I-67.
64. Lau CP, Tse HF, Jung W. Safety and efficacy of a human implantable defibrillation for atrial fibrillation. (Abstr.) Circulation 1996;94:I-562.
65. Tomassoni G, Newby KH, Kearney MM, Brandon MJ, Barold H, Natale A. Testing different biphasic waveforms and capacitances: effect on atrial defibrillation threshold and pain perception. J Am Coll Cardiol 1996;28:695-699.